Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03666325
Title Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle)
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

skin squamous cell carcinoma



Cetuximab + Pembrolizumab

Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.